NCT01649271View on ClinicalTrials.gov

Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

July 23, 2012

Primary Completion Date

June 23, 2016

Study Completion Date

June 23, 2016

Conditions
Breast NeoplasmsStomach Neoplasms
Interventions
DRUG

Herceptin

3-weekly

DRUG

afatinib

at MTD level

DRUG

trastuzumab

3-weekly

DRUG

Herceptin

weekly

DRUG

afatinib

at MTD level

DRUG

afatinib

escalating dose

Trial Locations (3)

21079

CTR Georges-François Leclerc, Dijon

31059

INS Claudius Regaud, Toulouse

44805

CTR René Gauducheau, Saint-Herblain

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY